Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $40.76 USD
Change Today +0.02 / 0.05%
Volume 386.1K
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Open
$40.47
Previous Close
$40.74
Day High
$41.87
Day Low
$40.27
52 Week High
05/20/15 - $42.43
52 Week Low
09/15/14 - $18.23
Market Cap
1.3B
Average Volume 10 Days
359.2K
EPS TTM
$0.27
Shares Outstanding
32.9M
EX-Date
--
P/E TM
153.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor and cell filtration products, which are used to increase cell growth and productivity during the fermentation step of biomanufacturing, and chromatography products for purification of biologic products. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality control test kits. Further, it has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yield during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

136 Employees
Last Reported Date: 03/17/15
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $218.7K
Chief Financial Officer
Total Annual Compensation: $150.8K
Vice President of Business Development
Total Annual Compensation: $271.0K
Senior Advisor
Total Annual Compensation: $222.1K
Senior Vice President of Research & Developme...
Total Annual Compensation: $302.0K
Compensation as of Fiscal Year 2014.

repligen corp (RGEN) Key Developments

Repligen Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

Repligen Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of USD 20,816,276 compared to USD 16,325,853 a year ago. Net income was USD 2,929,487 compared to USD 4,277,103 a year ago. Earnings per basic and diluted share were USD 0.09 compared to USD 0.13 a year ago. Income from operations was USD 4,038,898 against USD 5,307,869 a year ago. Income before income taxes was USD 4,198,473 against USD 5,398,105 a year ago. Non-GAAP EBITDA was USD 5,321,449 against USD 6,202,781 a year ago. Operating income for the first quarter was impacted by the recognition of USD 1.1 million in contingent consideration expense based on the high probability of the company achieving a 2015 sales milestone for the Alternating Tangential Flow (ATF) System Based on first quarter results and expectations for the remainder of 2015, the company is revising its financial guidance. The company expects revenue guidance for the year 2015 is USD 75 million -USD 78 million, an increase from previous guidance of USD 72 million -USD 75 million. Revenue projection for 2015 is comprised exclusively of bioprocessing product sales and reflects 24%-29% sales growth, an increase from previous guidance of 19%-24% growth. This guidance includes an estimated negative adjustment to sales growth of approximately 8% to accommodate the impact of foreign currency translation at current exchange rates. Product gross margin for the year 2015 is expected to be 56%-58%, an increase from previous guidance of 55%-57%. Total income from operations for the year 2015 is expected to be USD 14 million -USD 16 million, an increase from previous guidance of USD 12 million -USD 14 million. Net income is expected to be USD 10 million -USD 12 million, an increase from previous guidance of USD 8 million -USD 10 million.

Repligen Corporation to Report Q1, 2015 Results on May 07, 2015

Repligen Corporation announced that they will report Q1, 2015 results at 8:30 AM, US Eastern Standard Time on May 07, 2015

Repligen Corporation, Q1 2015 Earnings Call, May 07, 2015

Repligen Corporation, Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $40.76 USD +0.02

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGEN.
View Industry Companies
 

Industry Analysis

RGEN

Industry Average

Valuation RGEN Industry Range
Price/Earnings 100.0x
Price/Sales 19.6x
Price/Book 12.0x
Price/Cash Flow 196.2x
TEV/Sales 18.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit www.repligen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.